# A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

> **NCT04603833** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** SHR3680+Docetaxel
- **DRUG:** SHR3680
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04603833
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-02
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04603833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04603833, "A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04603833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*